Katamaran Capital LLP Acquires New Stake in Insulet Co. (NASDAQ:PODD)

Katamaran Capital LLP bought a new position in Insulet Co. (NASDAQ:PODD) during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 1,700 shares of the medical instruments supplier’s stock, valued at approximately $444,000. Insulet makes up approximately 0.6% of Katamaran Capital LLP’s portfolio, making the stock its 28th biggest holding.

Other institutional investors have also recently modified their holdings of the company. Integrated Wealth Concepts LLC increased its position in Insulet by 1.7% during the third quarter. Integrated Wealth Concepts LLC now owns 2,561 shares of the medical instruments supplier’s stock valued at $596,000 after acquiring an additional 42 shares during the last quarter. Horizon Investments LLC increased its position in shares of Insulet by 3.1% during the 4th quarter. Horizon Investments LLC now owns 1,387 shares of the medical instruments supplier’s stock valued at $362,000 after purchasing an additional 42 shares during the last quarter. Nisa Investment Advisors LLC lifted its stake in shares of Insulet by 1.0% in the 4th quarter. Nisa Investment Advisors LLC now owns 4,388 shares of the medical instruments supplier’s stock worth $1,146,000 after purchasing an additional 43 shares during the period. Graypoint LLC boosted its holdings in shares of Insulet by 5.3% in the fourth quarter. Graypoint LLC now owns 930 shares of the medical instruments supplier’s stock worth $243,000 after buying an additional 47 shares during the last quarter. Finally, Wilmington Savings Fund Society FSB grew its position in Insulet by 9.6% during the fourth quarter. Wilmington Savings Fund Society FSB now owns 538 shares of the medical instruments supplier’s stock valued at $140,000 after buying an additional 47 shares during the period.

Insulet Trading Down 4.5 %

Shares of PODD opened at $245.26 on Friday. The company’s fifty day moving average is $269.86 and its 200 day moving average is $259.53. Insulet Co. has a fifty-two week low of $160.19 and a fifty-two week high of $289.46. The company has a debt-to-equity ratio of 1.21, a quick ratio of 2.80 and a current ratio of 3.68. The stock has a market capitalization of $17.22 billion, a PE ratio of 42.36, a P/E/G ratio of 3.62 and a beta of 1.30.

Insulet (NASDAQ:PODD) last posted its quarterly earnings data on Thursday, February 20th. The medical instruments supplier reported $1.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.00 by $0.15. The business had revenue of $597.50 million during the quarter, compared to analyst estimates of $582.02 million. Insulet had a return on equity of 24.46% and a net margin of 20.19%. Sell-side analysts expect that Insulet Co. will post 3.92 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, EVP Eric Benjamin sold 12,394 shares of Insulet stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $280.00, for a total transaction of $3,470,320.00. Following the completion of the transaction, the executive vice president now directly owns 11,383 shares of the company’s stock, valued at approximately $3,187,240. The trade was a 52.13 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Wayne A.I. Frederick sold 1,825 shares of the stock in a transaction dated Tuesday, March 25th. The stock was sold at an average price of $275.00, for a total transaction of $501,875.00. Following the completion of the sale, the director now directly owns 3,231 shares in the company, valued at $888,525. This trade represents a 36.10 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.47% of the stock is owned by insiders.

Analysts Set New Price Targets

Several research analysts have weighed in on PODD shares. TD Cowen increased their price target on shares of Insulet from $264.00 to $324.00 and gave the stock a “buy” rating in a research report on Friday, January 3rd. Stifel Nicolaus lifted their target price on Insulet from $245.00 to $293.00 and gave the company a “hold” rating in a research report on Friday, February 21st. Raymond James reaffirmed an “outperform” rating and issued a $328.00 price objective (up previously from $294.00) on shares of Insulet in a research note on Friday, February 21st. Royal Bank of Canada began coverage on Insulet in a research note on Thursday, March 6th. They set an “outperform” rating and a $340.00 price objective for the company. Finally, Canaccord Genuity Group raised their target price on shares of Insulet from $304.00 to $324.00 and gave the stock a “buy” rating in a research note on Friday, February 21st. Four analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company’s stock. Based on data from MarketBeat, Insulet has an average rating of “Moderate Buy” and a consensus price target of $292.06.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.